01—Abstract
Summary
Summary of the 10-Q filed April 30, 2026. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. (DXCM) reported a strong first quarter for 2026, demonstrating significant top-line growth and substantial improvements in profitability.
Revenue increased by 15% year-over-year to $1.19 billiona, driven by increased sales volume of their continuous glucose monitoring (CGM) systems. This revenue growth, coupled with improved manufacturing efficiencies and a favorable product mix, led to a notable expansion in gross profit margin to 62.9% and a substantial 91% increase in operating income. The company also achieved robust net income growth of 89% to $199.5 million, translating to a diluted EPS of $0.51.
The balance sheet remains strong, with cash, cash equivalents, and short-term marketable securities totaling $2.42 billionb, providing ample liquidity. Operating cash flow saw a significant increase of 186% to $525.6 million, underscoring the company's operational efficiency and cash generation capabilities. Despite ongoing legal proceedings, DexCom appears to be navigating these challenges while continuing to invest in its core business and expand its market reach.
02—Key points
Key Highlights
- Revenue grew 15% year-over-year to $1.19 billion, driven by increased sales volume of CGM systems.
- Gross profit increased 27% to $750.3 million, with a gross margin of 62.9%, up from 56.9% in the prior year, reflecting manufacturing efficiencies.
- Operating income surged 91% to $255.3 million, indicating strong operational leverage.
- Net income more than doubled, rising 89% to $199.5 million, with diluted EPS of $0.51.
- Operating cash flow demonstrated significant strength, increasing 186% to $525.6 million.
- Cash, cash equivalents, and short-term marketable securities stood at a robust $2.42 billion as of March 31, 2026, providing strong liquidity.
- Selling, general, and administrative expenses increased by 13% primarily due to higher compensation, related costs, and increased advertising/marketing investments.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2026, Dexcom Inc kept $0.17.
- Revenue$1.19B100.0%
- Cost of revenue−$441.6M37.1%
- Gross profit$750.3M62.9%
- Operating costs−$495.0M41.5%
- Operating income$255.3M21.4%
- Interest, other & tax−$55.8M4.7%
- Net income$199.5M16.7%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2026filed April 30, 2026Financial Statements
Q1 FY2026 against Q1 FY2025
| Line item | Q1 FY2026Q1 FY2025 | Change |
|---|---|---|
| Revenue | $1.19B$1.04B | +15.0% |
| Cost of Revenue | $441.60M$447.00M | −1.2% |
| Gross Profit | $750.30M$589.00M | +27.4% |
| R&D Expenses | $145.30M$145.20M | +0.1% |
| SG&A Expenses | $349.70M$310.10M | +12.8% |
| Operating Expenses | $495.00M$455.30M | +8.7% |
| Operating Income | $255.30M$133.70M | +90.9% |
| Interest Expense | $2.10M$3.70M | −43.2% |
| Net Income | $199.50M$105.40M | +89.3% |
| EPS (Basic) | $0.52$0.27 | +92.6% |
| EPS (Diluted) | $0.51$0.27 | +88.9% |
| Shares Outstanding (Basic) | 385.10M391.10M | −1.5% |
| Shares Outstanding (Diluted) | 393.60M407.50M | −3.4% |
05—Questions
Frequently Asked Questions
What was Dexcom's revenue performance in the first quarter of 2026?
DexCom reported a 15% increase in revenue for the first quarter of 2026 compared to the same period in 2025, reaching $1.19 billion. This growth was primarily driven by an increase in the sales volume of their continuous glucose monitoring (CGM) systems, particularly disposable sensors, as they expanded their worldwide customer base.
How did Dexcom's profitability metrics change in Q1 2026?
DexCom showed significant improvements in profitability. Gross profit increased by 27% to $750.3 million, with the gross margin expanding to 62.9% from 56.9% in the prior year, attributed to manufacturing efficiencies. Operating income more than doubled, rising 91% to $255.3 million, and net income saw an 89% increase, reaching $199.5 million, which translated to a diluted EPS of $0.51.
What is Dexcom's current liquidity position?
As of March 31, 2026, DexCom maintained a strong liquidity position with $2.42 billion in cash, cash equivalents, and short-term marketable securities. The company also reported positive operating cash flow of $525.6 million for the quarter, indicating healthy cash generation from its core operations.
Are there any significant legal or contingent liabilities that investors should be aware of?
DexCom is involved in several ongoing legal proceedings, including securities class action litigation, derivative actions, and class action litigation related to their G6 and G7 devices. The company states that while they are defending these claims vigorously, the ultimate outcome is uncertain and could potentially have a material adverse effect on their business, financial condition, or results of operations. However, they do not believe they are party to any other currently pending legal proceedings that would have a material adverse effect.
06—Continue